Haisco Pharmaceutical gets trial approval for AMD drug, unlocks stock options

Haisco Pharmaceutical Group recently announced it received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its innovative drug HSK39297 tablets, targeting age-related macular degeneration (AMD). The company is approved to conduct clinical trials for this new indication, addressing a significant unmet medical need for AMD treatment.

Concurrently, Haisco Pharmaceutical also announced the first unrestricted period of its 2024 Restricted Stock Incentive Plan. A total of 6 core business and technical personnel, who met the performance assessment criteria, are eligible to unlock 1,740,000 shares of restricted stock, representing 0.1554% of the company's total share capital. The unlock date for these shares is set for November 19, 2025.

The company's 2024 operating revenue was RMB 3.721 bn, and it submitted 13 IND applications for drug candidates in 2024, exceeding the performance targets for the incentive plan. Following a semi-annual equity distribution, the reserved grant price for the incentive plan was adjusted from RMB 14.10 per share to RMB 13.955 per share.